Overview

Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China

Status:
NOT_YET_RECRUITING
Trial end date:
2027-08-07
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.
Phase:
PHASE3
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.